GlassScriptPhysician profile
Christopher M Mcguirk
NPI 1508818915
$3,048.37
in general payments reported to CMS, 2019-2025
35 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $262 · 2021: $419 · 2022: $266 · 2023: $542 · 2024: $632 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.96 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $484.82 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $440.88 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $219.19 | 2019-2025 | |
| Exeltis, USA INC. | $218.75 | 2019-2025 | Slynd |
| Avion Pharmaceuticals | $179.19 | 2019-2023 | Balcoltra, NP Thyroid 60 |
| Sumitomo Pharma America, INC. | $172.14 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $133.29 | 2021-2024 | |
| Pfizer INC. | $126.20 | 2019-2023 | |
| Daiichi Sankyo INC. | $124.10 | 2019-2021 | |
| Organon LLC | $84.33 | 2022-2024 | Nexplanon |
| Axonics, INC. | $81.66 | 2024 | Axonics |
| Biogen, INC. | $79.85 | 2021-2024 | Zurzuvae |
| Therapeuticsmd, INC. | $70.76 | 2019-2020 | |
| Millicent US INC | $64.43 | 2023 | Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $54.62 | 2019-2023 | Gardasil 9 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $41.61 | 2019 | |
| Allergan, INC. | $39.88 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $39.74 | 2021-2024 | Exparel |
| Aspira Women'S Health INC | $35.18 | 2024 | Ova1 |
| Amag Pharmaceuticals, INC. | $34.55 | 2019-2020 | |
| Hologic Sales and Service, LLC | $34.28 | 2019-2025 | Thinprep 2000 Processor |
| Mission Pharmacal Company | $30.36 | 2019-2021 | |
| Shield Therapeutics INC | $28.70 | 2023-2024 | Accrufer |
| Ethicon US, LLC | $26.41 | 2025 | Enseal |
| Smith+Nephew, INC. | $25.26 | 2025 | Pico 7 |
| Scynexis, INC. | $24.23 | 2022 | |
| Optumhealth Care Solutions, LLC | $23.68 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Myovant Sciences INC. | $21.86 | 2022 | |
| Mimedx Group, INC. | $21.85 | 2025 | |
| Baxter Healthcare | $20.71 | 2024 | Perclot |
| Karl Storz Endoscopy-America | $20.44 | 2019 | |
| Evofem Biosciences, INC. | $17.70 | 2023 | Phexxi |
| Vertical Pharmaceuticals, LLC | $15.28 | 2019 | |
| Amgen INC. | $12.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mcguirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.